Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
370 Leser
Artikel bewerten:
(1)

Learning 2 Sleep L2S AB begins collaboration with Funmed AB, Europe's largest medical clinic in precision health and functional medicine

Finanznachrichten News

The digital healthcare provider Learning 2 Sleep L2S AB (L2S) has signed a cooperation agreement with the medical clinic Funmed AB (Funmed). The collaboration aims to provide effective treatment in a flexible way for people who have undergone a health analysis with Funmed and who have sleep problems.

Funmed is Europe's largest medical clinic in precision health and functional medicine, aiming to search for and treat underlying causes of disease and illness. The collaboration with the digital sleep clinic L2S will function as an extension of Funmed's offer where L2S can offer help to individuals who in Funmed's analysis are found to have sleep problems.

Good sleep is fundamental for both physical and mental health and L2S offers the most qualitative and effective sleep treatment on the market. The parties share a fundamental vision that individuals should receive help with their health problems early to avoid more serious illnesses. In addition to this, it is important that people with sleep problems are offered cognitive behavioral therapy (CBT) as a first-line option in accordance with the National Board of Health and Welfare guidelines. The collaboration will help those individuals who have a sleep problem, where it is justified to start a CBT treatment, and where we know that the treatment has a good effect.

"For L2S, it is extremely important that sleep problems are treated at an early stage and with the treatment that gives the best effect in the long term. CBT should be recommended in the first instance, but due to a lack of time and resources in healthcare, it is more common today for people with sleep problems to be offered prescription sleep medications. L2S wants to break this trend and sees the collaboration with Funmed as an important step in achieving our vision that every person with sleep problems should get the right help." says Lina Johansson, licensed psychologist, and CEO of Learning to Sleep.

"Sleep is not just for resting the brain as many people unfortunately think. Sleep is absolutely central to good health and quality sleep is a prerequisite for a number of biochemical processes in the body. Funmed's treatment program searches for and remedies the underlying causes of ill health. An important component to reaching our goal of a healthy patient is sleep. Therefore, we want to support the patient to sleep both enough and with good quality. In order to offer the best possible support to our patients, it was therefore completely natural for Funmed to enter into a partnership with L2S as Sweden's leading healthcare provider in sleep therapy." says Peter Martin, founder, and CEO at Funmed.

The collaboration will start in March 2023. The company does not currently provide a forecast of what it will generate in terms of turnover but expects that a successful collaboration is expected to have a positive impact on the influx of patients. However, no expected volumes can be given at the moment.

About Learning to Sleep
Learning to Sleep is a digital healthcare provider specializing in the treatment of chronic sleep disorders. The treatment is a combination of a structured treatment program in a mobile application and weekly digital meetings with a psychologist. The company's treatment is based on the latest research in the field and is very successful - over 90 percent of the patients treated get improved sleep. Sweden is the company's main market and the treatment is offered as part of the tax-financed care choice.
For more information see www.learningtosleep.se
The company's Certified Adviser is Eminova Fondkomission AB | 08-684, 211 10 | adviser@eminova.se

About Funmed
Funmed is Europe's largest medical clinic in precision health and functional medicine, with digital and physical receptions all over the country. With the support of research and advanced tests and measurement methods, Funmed takes a comprehensive approach to each individual's personal health and can thus better manage complex chronic diseases and symptoms. The tests that are performed provide the pieces of the puzzle that are often overlooked in traditional care.
See more at www.funmed.se

Contacts

For more information please contact:

Lina Johansson, VD
Mobil: 0709-243193
E-post: lina@learningtosleep.se

© 2023 GlobeNewswire (Europe)
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.